Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Part of paid clinical trials in Daphne, Alabama.

Sponsor
Pfizer
Study ID
NCT00321815
Phase
PHASE2
Status
Completed

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PF-3512676 + Erlotinib — DRUG
    PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity. Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
  • Erlotinib — DRUG
    Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity

Study Details

To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Key Dates

First listed
May 4, 2006
Start date
Aug 31, 2006
Status verified
Dec 2010
Primary completion
Jun 30, 2010
Completion
Jun 30, 2010

Study Design

Enrollment
43 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A
    Standard of Care chemotherapy plus experimental intervention (PF-3512676)
  • Active Comparator: B
    Standard of Care chemotherapy

Primary Outcome Measure

Progression-Free Survival [ Time Frame: 50Events ]

Locations (35)

FacilityCityStateZIPSite coordinators
Pfizer Investigational SiteDaphneAlabama36526-
Pfizer Investigational SiteHuntsvilleAlabama35805-
Pfizer Investigational SiteMobileAlabama36608-
Pfizer Investigational SiteCoronaCalifornia92879-
Pfizer Investigational SiteGlendoraCalifornia91741-
Pfizer Investigational SiteGreenbraeCalifornia94904-
Pfizer Investigational SitePasadenaCalifornia91105-
Pfizer Investigational SitePomonaCalifornia91767-
Pfizer Investigational SiteRancho CucamongaCalifornia91730-
Pfizer Investigational SiteSan MateoCalifornia94402-
Pfizer Investigational SiteWest CovinaCalifornia91790-
Pfizer Investigational SiteNorwalkConnecticut06856-
Pfizer Investigational SiteDeerfield BeachFlorida33442-
Pfizer Investigational SiteMelbourneFlorida32901-
Pfizer Investigational SiteMiamiFlorida33136-
Pfizer Investigational SiteMunsterIndiana46321-
Pfizer Investigational SiteMason CityIowa50401-
Pfizer Investigational SiteCrestview HillsKentucky41017-
Pfizer Investigational SiteLouisvilleKentucky40202-
Pfizer Investigational SiteBridgetonMissouri63044-
Pfizer Investigational SiteChesterfieldMissouri63017-
Pfizer Investigational SiteKirkwoodMissouri63122-
Pfizer Investigational SiteSomervilleNew Jersey08876-
Pfizer Investigational SiteNew YorkNew York10016-
Pfizer Investigational SiteStony BrookNew York11794-
Pfizer Investigational SiteCincinnatiOhio45209-
Pfizer Investigational SiteCincinnatiOhio45219-
Pfizer Investigational SiteFairfieldOhio45014-
Pfizer Investigational SiteHersheyPennsylvania17033-0850-
Pfizer Investigational SitePhiladelphiaPennsylvania19104-
Pfizer Investigational SitePhiladephiaPennsylvania19104-
Pfizer Investigational SiteKingsportTennessee37660-
Pfizer Investigational SiteDallasTexas75230-
Pfizer Investigational SiteDallasTexas75246-
Pfizer Investigational SiteDallsTexas75246-

Find similar trials in Daphne, AL

By research site
Pfizer Investigational Site· Daphne, ALPfizer Investigational Site· Huntsville, ALPfizer Investigational Site· Mobile, ALPfizer Investigational Site· Corona, CAPfizer Investigational Site· Glendora, CAPfizer Investigational Site· Greenbrae, CA

Related Studies